Compare Adaptive Biotechnologies Corp (ADPT) vs Trade Desk Inc (TTD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Trade Desk Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Trade Desk Inc trades at $18.95 (market cap $9.02B). The key difference: Trade Desk Inc is far larger — about 2.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | TTD | |
|---|---|---|
Market Cap | $3.33B | $9.02B |
Sector | Health | Technology |
52-Week High | $22.37 | $89.76 |
52-Week Low | $10.24 | $17.33 |
Enterprise Value | $3.19B | $8.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
The Trade Desk (TTD) trades at $19.18, up 0.42% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though Q1 2026 earnings missed expectations. Revenue growth has been consistent, reaching $2.9B in 2025, while analyst sentiment remains divided with a $25.46 consensus target representing 33% upside potential.
TTD presents a compelling value opportunity with reasonable valuations (P/E 21.94, P/S 3.17) and strong cash flow generation, but faces near-term headwinds from recent earnings miss and competitive pressures in digital advertising. The stock's 86% decline from 2024 highs creates potential for recovery if execution improves, though investor caution is warranted given mixed analyst ratings and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
